MedTrace Logo

Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial Intelligence

NCT05587452 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 950

Last updated 2022-10-24

No results posted yet for this study

Summary

To evaluate the accuracy and effectiveness of a novel screening method based on plasma multi-omics combining with artificial intelligence in a large prospective cohort for the detection of colorectal cancer and advanced adenomas.

Conditions

Interventions

DIAGNOSTIC_TEST

Colonoscopy

Colonoscopy is performed to identify whether the patient has colorectal adenoma or cancer

DIAGNOSTIC_TEST

Test of ctDNA methylation

A specified panel is used to detect the site of methylation of ctDNA in plasma

DIAGNOSTIC_TEST

Test of characteristics of ctDNA fragment

Low pass whole genome sequencing is used to detect the characteristics of ctDNA fragment

Sponsors & Collaborators

  • Cangzhou Central Hospital

    collaborator OTHER

  • Weifang Medical University

    collaborator OTHER

  • Heji Hospital affiliated to Changzhi Medical College

    collaborator UNKNOWN

  • Beijng Fengtai Hospital

    collaborator UNKNOWN

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-05-01
Completion
2025-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05587452 on ClinicalTrials.gov